This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Endo, Impax sued by US FTC for allegedly agreeing to eliminate competition for oxymorphone ER

( January 25, 2021, 21:05 GMT | Official Statement) -- MLex Summary: The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories and Impax’s owner, Amneal Pharmaceuticals, alleging that they illegally conspired to limit competition in the market for oxymorphone ER, a painkiller. According to the complaint, Endo reached an agreement with Impax, the only other authorized seller of an oxymorphone ER product, to share Impax’s monopoly profits, with Endo in the role of a potential entrant paid to stay out of the market.Statement follows in full. Also see document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections